October 23, 2012
While Regeneron (Nasdaq: REGN ) doesn't rank among top performers in the Nasdaq Composite, its year-to-date performance is still nothing short of impressive. Shares have risen around 180% and boosted the company's market capitalization to nearly $15 billion on the strength of Eylea, the company's flagship drug targeting age-related macular degeneration. The company reports earnings Wednesday, and as is the case for many high-flying stocks, hitting Wall Street's revenue estimates and offering strong guidance for the future will play a vital role in the direction shares take.
In the following video, health care bureau chief Brenton Flynn outlines the competitive environment for Regeneron's Eylea, including one low-priced drug that could turn out to be its biggest competition.
When it comes to do-or-die business, the biotech industry takes the cake. Arena Pharmaceuticals is one recent success story in the industry after gaining FDA approval for its innovative obesity drug. While the future looks bright for Arena, there are still plenty of obstacles ahead. In our brand new premium research report on Arena Pharmaceuticals, we walk investors through the must-know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for those who sign up. Click here now to learn more.